[9] [12] [17] Developed by Eli Lilly and Company, tirzepatide was approved for treatment of diabetes in the US in May 2022, [9] [12] in the European Union in September 2022, [11] in Canada in November 2022, [18] and in Australia in December 2022
Key developments include increased scrutiny of compounded semaglutide, evolving FDA guidance, pharmacy sourcing requirements, and patient safety expectations
A wrong assumption can lead to a dose that is dramatically higher or lower than intended
Cholesterol and lipid changes Lipid panels begin improving within the first three months, though the full effect takes six months or longer to manifest
This man cares about his patients
Rated 5 out of 5 Anonymous (verified owner) Product works great and I havent had any issues with any side effects